Can we currently sequence ADCs in ovarian cancer?
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, comments on the limitations of sequencing antibody-drug conjugated (ADCs) in ovarian cancer, highlighting the need for well-designed clinical trials to address the question of prioritizing drugs based on target expression and payload. The current FDA approvals for mirvetuximab soravtansine and trastuzumab deruxtecan provide a starting point, but further research is needed to determine the optimal sequencing and payload combinations. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
